Results 131 to 140 of about 414,372 (151)

Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes. [PDF]

Diabetol Int
Oya J, Nakagami T, Hasegawa Y, Kondo Y, Katamine A, Shimizu M, Kubota R, Suda R, Babazono T.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Insulin Aspart

Drugs, 2012
Caroline M Spencer, C M Spencer
exaly   +4 more sources

Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise

Diabetes Technology and Therapeutics, 2022
David O'Neal, Sara Vogrin, Melissa H Lee
exaly  

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

Diabetes, Obesity and Metabolism, 2015
T Heise
exaly  

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

Clinical Pharmacokinetics, 2017
Tim Heise, Thomas Danne, Thomas Pieber
exaly  

Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes*

Journal of Diabetes, 2016
Gregory R Fulcher, Søren Rasmussen, Jens Sandahl Christiansen   +2 more
exaly  

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)

Diabetes Care, 2020
Giorgio Sesti, Hak Chul Jang, Wendy S Lane   +2 more
exaly  

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Diabetologia, 2006
Michael A. Nauck, D Johns, Andreas Festa
exaly